Navigation Links
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
Date:8/29/2014

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering.

Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body.

The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems.

Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.

The analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.

The report, the Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Product Profiles

05. Market Research Methodology

06. Introduction

07. Rate of Incidence and Prevalence

08. Market Segmentation by Molecule Type

09. Market Segmentation by Route of Administration

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

19. Key Vendor Analysis

20. Other Reports in this Series

Companies Mentioned:

  • Americas
  • APAC
  • EMEA Key Vendors
  • Bayer
  • Biogen Idec
  • Merck Serono
  • Novartis
  • Teva Pharmaceutical
  • AB Science
  • Abbvie
  • Acorda
  • Active Biotech
  • GlaxoSmithKline
  • Glenmark
  • Mitsubishi Tanabe
  • Opexa
  • Pfizer
  • Sanofi

For more information visit http://www.researchandmarkets.com/research/z9b74c/global_multiple

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew
2. Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company
3. Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research
4. Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit
5. DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
6. Global Pulse Oximeter Industry Report 2014
7. Global Orthopedic Soft Tissue Repair Devices Market 2014-2018
8. Global Heart Valve Repair and Replacement Market 2014-2018
9. Hill-Rom to Participate in the Morgan Stanley Global Healthcare Conference
10. Global Animal Health Market 2014-2018
11. Columbia Laboratories to participate in the Rodman & Renshaw 16th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  A new survey ... that Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary ... The lack of choice forces beneficiaries to switch to ... health consequences. AADE,s survey is the ... and others pointing out the inherent problems with the ...
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com News ... According to a new ... North America , grew 34 percent to $6.7 billion and ... rate of (CAGR) over the next five years, from $6.7 billion in ... of Americans that will be able to purchase cannabis without a doctor,s ...
(Date:3/27/2017)... Mass. , March 27, 2017   Pulmatrix, Inc ... inhaled therapies to address serious pulmonary diseases, today announced that ... fungal disease, cystic fibrosis and asthma to its Scientific ... Richard B. Moss , MD, former ... Director of the Cystic Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... Arlington, VA (PRWEB) , ... March 27, 2017 ... ... version 3.0 was transitioned to the OSEHRA popHealth Community in 2014. ... Steering Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... training, today announced the launch of a new research study, The Business Readiness ... needed to execute that strategy, and the actual success of achieving individual and ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... According ... with prostate cancer, including all stages, is more than 95%. Once the cancer spreads ... to less than 30%. To find out how to avoid this latter group, tune ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency ... on Monday, April 3rd to commemorate the two-year anniversary of the facility. The ... to celebrate two great years while also familiarizing themselves with the facility. , ...
Breaking Medicine News(10 mins):